Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Flamel, GSK Augmentin formulation deal

Flamel (FLML) licensed to GlaxoSmithKLine (GSK; LSE:GSK) its

Read the full 86 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE